uttroside-B (Utt-B) / Q BioMed - LARVOL DELTA

Complex engineering of Solanum alkaloids structural diversity in Nicotiana benthamiana. (PubMed, Plant Biotechnol J) - "Furthermore, we engineered the biosynthetic pathway of the steroidal saponins uttroside B, dehydrouttroside B, and their stereoisomers [25(S)-uttroside B and 25(S)-dehydrouttroside B]. Production of these metabolites in N. benthamiana opens broad possibilities for examining and exploring their therapeutic potential. This study therefore makes a significant contribution to the application of synthetic biology for producing high-value steroidal metabolites in heterologous plant hosts."

Journal • Oncology

A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma. (PubMed, Anticancer Agents Med Chem) - "Our results highlight the potential of Utt-B as an effective chemosensitizer, which can augment the efficacy of Sor against HCC and circumvent Sor-induced toxic side effects. Moreover, this is the first and only report to date on the chemosensitizing potential of Utt-B and the only report that demonstrates the therapeutic efficacy and pharmacological safety of a novel combinatorial regimen involving Utt-B and Sor for combating HCC."

Journal • Orphan drug • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • ANXA5 • CASP7

Enhanced extracellular vesicles mediated uttroside B (Utt-B) delivery to Hepatocellular carcinoma cell: Pharmacokinetics based on PBPK modelling. (PubMed, Biochem Biophys Res Commun) - "We further analysed drug-releasing kinetics and simulated the Pharmacokinetics by PBPK modelling. The simulated pharmacokinetics revealed the bioavailability of Uttroside-B in oral administration against intravenous administration."

Journal • PK/PD data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Solanum nigrum Linn.: Advances in anti-cancer activity and mechanism in digestive system tumors. (PubMed, Med Oncol) - "include solanine, solasonine, solamargine, a-L-rhhamnopyranose, uttroside B, degalactotigonin, glycoprotein, and other compounds...nigrum Linn. has great potential in the treatment of tumors of the digestive system, and through further clinical trials and pharmacological mechanisms it has the potential to become a uniform and standardized anti-tumor drug."

Journal • Review • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe (PRNewswire) - "Q BioMed Inc...a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – has received a patent in the United States and a notice of allowance in Europe, adding to the already issued patents in Korea, Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program."

Patent • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer (PRNewswire) - "Q BioMed, Inc...announces a new publication supporting the potential superior safety and efficacy of its Uttroside-B chemotherapeutic to treat liver cancer vs the current first line FDA approved drug...The therapeutic efficacies of Utt-B vs. sorafenib against HCC were compared in vitro, using various liver cancer cell lines and in vivo, utilizing mice bearing human xenografts. The data indicate that Utt-B shows superior anti-HCC efficacy over sorafenib...This innovation has been granted a patent from the US, Canada, Japan and South Korea..."

Patent • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Impedance of autophagy improves the potency of uttroside B, a US FDA-approved 'orphan drug' against hepatocellular carcinoma (EACR 2022) - "Our study revealed that inhibition of autophagy using the antimalarial drug, Chloroquine (Cqn), a well-known autophagy inhibitor, significantly enhances the antitumor efficacy of Utt-B in vitro and in vivo, in NOD SCID mice bearing HCC xenografts. Conclusion Our results suggest that Utt-B is a more potent anti-HCC drug than sorafenib and the antitumor effect of Utt-B against HCC can be further enhanced by blocking autophagy. Hence, Utt-B in combination with Cqn, a clinically approved drug, if repurposed and used in a combinatorial regimen with Utt-B, can further improve the therapeutic efficacy of Utt-B against HCC."

FDA event • Orphan drug • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor • BECN1 • PRKDC

The phyto-saponin, Uttroside B, displays an augmented therapeutic index over sorafenib in a pre-clinical model of hepatocellular carcinoma (EACR 2022) - "Conclusion Our data demonstrate the superior therapeutic index of Utt-B over sorafenib against HCC. Clinical studies in HCC patients utilizing Utt-B, which now holds the U.S. FDA approval as an 'orphan drug’ is an essential step to promote this drug from bench to bedside."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • PRKDC

Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma. (PubMed, Pharmaceuticals (Basel)) - "Here, we show that higher concentrations of sorafenib induce severe toxicity, in Chang Liver, as well as in acute and chronic in vivo models, indicating that, apart from the superior therapeutic benefit over sorafenib, Utt-B is a pharmacologically safer molecule, and the drug-induced undesirable effects can, thus, be substantially alleviated in the context of HCC chemotherapy. Clinical studies in HCC patients utilizing Utt-B, is a contiguous key step to promote this drug to the clinic."

Journal • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • PRKDC

Blockade of Uttroside B-Induced Autophagic Pro-Survival Signals Augments Its Chemotherapeutic Efficacy Against Hepatocellular Carcinoma. (PubMed, Front Oncol) - "We further analyzed whether the antimalarial drug, Chloroquine (Cqn), a well-known autophagy inhibitor, can enhance the anticancer effect of Utt-B against HCC. Taken together, our results suggest that the antitumor effect of Utt-B against HCC can be further enhanced by blocking autophagy. Furthermore, Utt-B in combination with Cqn, a clinically approved drug, if repurposed and used in a combinatorial regimen with Utt-B, can further improve the therapeutic efficacy of Utt-B against HCC."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Oncology • Solid Tumor • BECN1

Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer (PRNewswire) - “Q BioMed Inc…announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.”

Orphan drug • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology

Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan (PRNewswire) - "Q BioMed Inc...announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled 'Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma' is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma...'We expect to initiate our first preclinical tests and anticipate preparing Uttroside-B for an investigational new drug (IND) application with the U.S. FDA before year end'..."

IND • Patent • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer (PRNewswire) - "Q BioMed...announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In preclinical studies, Uttroside-B was up to 10-times more potent against HCC cells than Sorafinib, the standard of care drug at the time....Preclinical testing is now underway to support an FDA Investigational New Drug (IND) application expected this year."

IND • Orphan drug • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology

"#QBioMed's Uttroside-B Receives U.S. Patent in Treatment of #LiverCancer $QBIO https://t.co/uTsszt0SLv" (@1stOncology)

Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Q BIOMED TO SCALE UP PRODUCTION OF UTTROSIDE-B, A NOVEL CHEMOTHERAPEUTIC FOR LIVER CANCER, IN PREPARATION FOR IND FILING (PharmiWeb) - "Q BioMed, Inc...and Chemveda Life Sciences are very pleased to continue their collaboration on Uttroside-B, a chemotherapeutic that has shown remarkable potential efficacy as a treatment for liver cancer...Q BioMed CEO said, “Having successfully completed a very challenging synthesis program, we are pleased to be able to advance this important asset towards the clinic and the patients we hope to treat."

Clinical • Licensing / partnership • Oncology

Emerging themes of regulation of oncogenic proteins by Solanum nigrum and its bioactive molecules in different cancers. (PubMed, J Cell Biochem) - "Several worthy of mention include uttroside B, solanine, solamargine, and physalins, which have been tested for efficacy in cancer cell lines and xenografted mice...We also provide an overview of new tools, methodologies, and approaches, which will allow researchers to extract as much information as possible out of the tremendous data sets currently being generated. The use of computational tools will be helpful in processing structurally complex natural products and also in prediction of their macromolecular targets."

Journal

Newly added product (PRNewswire) - Preclinical, HCC

Pipeline update